Effects of tiludronate on bone loss in paraplegic patients
Effects of tiludronate on bone loss in paraplegic patients
复制标题
替鲁膦酸钠对截瘫患者骨丢失的影响
DOI：
10.1002/jbmr.5650100116
复制
发表时间：
1992
影响因子：
6.2
通讯作者：
C. Gaud
中科院分区：
文献类型：
--
作者：
D. Chappard;P. Minaire;C. Privat;E. Bérard;J. Mendoza‐Sarmiento;H. Tournebise;M. Baslé;M. Audran;A. Rebel;C. Picot;C. Gaud
继发于脊髓损伤的制动与骨小梁的显著和快速萎缩有关（废用性骨质疏松）。这是由于成骨细胞骨吸收的早期增加与成骨细胞骨形成的显著减少有关。双膦酸盐是一种抗骨质疏松的化合物，在预防废用性骨质疏松症方面有一定的作用。然而，它们中的一些也抑制成骨细胞活性，并可能损害矿化过程。替鲁膦酸盐在几种代谢性骨疾病中显示出有效减少骨吸收而不诱导矿化缺陷。20例截瘫患者（6例女性和14例男性）被随机分配到3组：6例患者进入安慰剂组; 7例患者接受替鲁膦酸盐200 mg/天; 7例患者接受400 mg/天。在治疗3个月之前和之后对经髂骨骨活检进行组织形态计量学分析。在安慰剂组和200 mg组中观察到骨体积的不显著减少。在接受400 mg/天的患者中，观察到轻微增加。三组中的类骨质参数变化不显著，尽管400 mg组显示出类骨质体积和厚度轻微下降的趋势。所有组的侵蚀表面均增加。安慰剂组破骨细胞数量（通过TRAP染色进行组织化学鉴定）增加，但替鲁膦酸盐组破骨细胞数量减少。替鲁膦酸盐似乎有效地减少骨吸收，而不损害骨形成的方式，保持骨量和骨细胞耦合。
Immobilization secondary to spinal cord injury is associated with a marked and rapid atrophy of trabecular bone (disuse osteoporosis). This is due to an early increase of osteoclastic bone resorption associated with a pronounced decreased osteoblastic bone formation. Bisphosphonates are antiosteoclastic compounds and they have been effective in preventing disuse osteoporosis. However, some of them also depress osteoblastic activity and may impair the mineralization process. Tiludronate was shown effective in reducing bone resorption in several metabolic bone diseases without inducing mineralization defects. Twenty paraplegic patients (6 females and 14 males) were randomly assigned to three groups: 6 patients entered the placebo group; 7 patients received tiludronate 200 mg/day; and 7 received 400 mg/day. Histomorphometric analysis was performed on transiliac bone biopsies before and after 3 months treatment An insignificant decrease of bone volume was observed in the placebo group and the 200 mg group. In patients receiving 400 mg/day, a slight increase was noted. Osteoid parameters changed nonsignificantly in three groups although the 400 mg group exhibited a slight tendency to decrease osteoid volume and thickness. Eroded surfaces increased in all groups. The number of osteoclasts (identified histochemically by TRAP staining) increased in the placebo group but decreased in groups receiving tiludronate. Tiludronate appears effective in reducing bone resorption without impairing bone formation in a manner that preserved bone mass and bone cell coupling.
影响因子：
158.5
作者：
BRACKEN, MB;SHEPARD, MJ;WINN, HR
通讯作者：
WINN, HR
DOI：
10.1115/1.2895536
发表时间：
1993-11-01
影响因子：
1.7
作者：
KEAVENY, TM;HAYES, WC
通讯作者：
HAYES, WC